Keenova Therapeutics plc SEC Filings

Filed On	Filing
06 Oct 2026	Form 4: Goldentree Asset Management Lp, 10% owner and 2 others Bought 463,000 shares ($42.1M)
06 Oct 2026	SCHEDULE 13D/A
11 Aug 2026	10-Q
11 Aug 2026	8-K: Results of Operations and Financial Condition
03 Aug 2026	8-K: Other Events
23 Jul 2026	Form 4: Williamson Susan Ann, EVP & Chief Compliance Officer Gave up 571 shares to cover exercise price or tax
23 Jul 2026	Form 4: Basso Tracy, EVP & CHRO Gave up 763 shares to cover exercise price or tax
23 Jul 2026	Form 4: Stouch Cheryl Ann, EVP & Chief Info Officer Gave up 328 shares to cover exercise price or tax
17 Jul 2026	Form 4: Langlois Sophia J., Director Granted 4,406 Restricted Stock Units
17 Jul 2026	Form 4: Yoskowitz Marc J, Director Granted 4,406 Restricted Stock Units
17 Jul 2026	Form 4: Hirsch Scott, Director Granted 4,406 Restricted Stock Units
17 Jul 2026	Form 4: Zinman Jon, Director Granted 4,406 Restricted Stock Units
17 Jul 2026	Form 4: Efron Paul, Director Granted 4,406 Restricted Stock Units
17 Jul 2026	Form 4: Donato Leslie E, Director Granted 4,406 Restricted Stock Units
17 Jul 2026	Form 4: Dorton Katina, Director Granted 4,406 Restricted Stock Units
17 Jul 2026	Form 4: Bisaro Paul, Director Granted 4,406 Restricted Stock Units
17 Jul 2026	Form 4/A: Donato Leslie E, Director Received 2,685 shares by exercise or conversion · Gave up 619 shares to cover exercise price or tax · Disposed of 2,197 Restricted Stock Units (Disposition to Issuer)
08 Jul 2026	8-K: Regulation FD Disclosure; Other Events
15 Jun 2026	8-K: Other Events
04 Jun 2026	Form 4: Langlois Sophia J., Director Received 2,685 shares by exercise or conversion · Gave up 1,289 shares to cover exercise price or tax · Disposed of 2,197 Restricted Stock Units (Disposition to Issuer)

Comments